The selection of immune checkpoint inhibitors of programmed cell death (anti-PD-1) and its ligand (anti-PD-L1) makes matters more challenges for clinical practice.

Wang, Peng-Hui; Yang, Szu-Ting; Liu, Chia-Hao

Wang, Peng-Hui; Yang, Szu-Ting; Liu, Chia-Hao.

Affiliation

Wang PH; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Female Cancer Foundation, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. Electronic address: phwang@vghtpe.gov.tw.
Yang ST; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Liu CH; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Taiwan J Obstet Gynecol ; 63(4): 448-450, 2024 Jul.

Article in En | MEDLINE | ID: mdl-39004469

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B7-H1 Antigen / Programmed Cell Death 1 Receptor / Immune Checkpoint Inhibitors Limits: Female / Humans Language: En Journal: Taiwan J Obstet Gynecol / Taiwan. j. obstet. gynecol / Taiwanese journal of obstetrics & gynecology Journal subject: GINECOLOGIA / OBSTETRICIA Year: 2024 Document type: Article Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google